Angiogenesis Inhibitors

This page contains recent news articles, when available, and an overview of Angiogenesis Inhibitors but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

News: Angiogenesis Inhibitors

Scrubbing In: Drug working wonders on cancer and clouded vision  -  23 Nov 2009
Philadelphia InquirerAnd 10 angiogenesis inhibitors have been approved. It's a thrill, as I train, to be a small part of this revolution. Wills Eye, which has the largest retina ...

Acceleron Pharma Initiates First-in-Human Study of ACE-041, a Novel ...  -  ‎Nov 4, 2009‎
Reuters..."There is a tremendous need for novel angiogenesis inhibitors in cancer. The first generation treatments, while ground-breaking, ultimately showed that VEGF ...

AACR-NCI-EORTC conference highlights major expansion in cancer drug pipeline  -  ‎Nov 17, 2009‎
News-Medical.netBreakthroughs to date have been made in the development of anti-angiogenesis inhibitors that target the tumor vasculature and of modulators of gene ...

New Mechanism Explains How The Body Prevents Formation Of Blood Vessels  -  ‎Nov 11, 2009‎
Science Daily (press release)...responsible for the inhibitory effect is present in human tissue, which suggests that it serves as one of the body's own angiogenesis inhibitors. ...

Pancreatic Cancer Report Urges Changes in Clinical Trials  -  ‎Nov 3, 2009‎
National Cancer Institute - NCI Cancer BulletinWith the exception of erlotinib (Tarceva), which has only a marginal benefit, the targeted drugs tested to date, including angiogenesis inhibitors, ...

OXiGENE Reports Third Quarter 2009 Financial Results  -  ‎Nov 8, 2009‎
CNNMoney.com (press release)...in various combination regimens with chemotherapy, molecularly-targeted therapies (including tumor-angiogenesis inhibitors), and radiation therapy. ...

OXiGENE to Present at American Society of Hematology and AACR/NCI/EORTC Meetings  -  ‎Nov 12, 2009‎
FOXBusiness...in various combination regimens with chemotherapy, molecularly-targeted therapies (including tumor-angiogenesis inhibitors), and radiation therapy. ...

ACT BIOTECH Announces Treatment of First Gastric Cancer Patients ...  -  ‎Jul 30, 2009‎
Business Wire (press release)...“Telatinib is a promising oral drug of the well-established class of angiogenesis inhibitors to treat patients with gastric or gastroesophageal

OXiGENE Reports Second Quarter 2009 Financial Results; Company ...  -  ‎Jul 29, 2009‎
Trading Markets (press release)...in various combination regimens with chemotherapy, molecularly-targeted therapies (including tumor-angiogenesis inhibitors) and radiation therapy.

Therapy for the treatment of the mesothelioma cancer  -  ‎Jul 21, 2009‎
Mesothelioma Cancer News (press release)A number of anti drugs, known as the anti angiogenesis drugs, that act as angiogenesis inhibitors, have been developed. A few of them have been tested on

Learning To See With Macular Degeneration  -  ‎Jul 31, 2009‎
TheDenverChannel.comTreatments for wet macular degeneration include drugs called angiogenesis inhibitors (Lucentis, Macugen); photocoagulation, which involves using a

PolyMedix Gets US Patent for Angiogenesis Inhibitor Compounds  -  ‎Jul 20, 2009‎
Trading Markets (press release)PolyMedix's angiogenesis inhibitors may have a mechanism of action distinct from compounds that only inhibit VEGF (vascular endothelial growth factor).

BiomedReports: FDA and News Updates for Pfizer Inc.(NYSE:PFE ...  -  ‎Jul 16, 2009‎
Trading Markets (press release)...announced that the United States Patent and Trademark Office issued a patent assigned to PolyMedix relating to angiogenesis inhibitors.

PolyMedix Receives United States Patent for Angiogenesis Inhibitor ...  -  ‎Jul 16, 2009‎
PharmaLive.com (press release)PolyMedix's angiogenesis inhibitors may have a mechanism of action distinct from compounds that only inhibit VEGF (vascular endothelial growth factor).

New Technology Could Help Diagnose Alzheimer's  -  Dec 9, 2008
Boston Channel.com,...the effect of treatments, particularly new cancer drugs that work to cut off the blood supply to tumors, drugs known as angiogenesis inhibitors.

Decision Biomarkers Inc Announces Formation of Scientific Advisory ...  -  Dec 2, 2008
MarketWatch...translational and laboratory research is to advance the development of targeted agents, particularly angiogenesis inhibitors for non-small lung cancer,

OXiGENE Stockholders Approve Share Issuance to Symphony Capital  -  Dec 9, 2008
GlobeNewsWire (press release),...in various combination regimens with chemotherapy, molecularly-targeted therapies (including tumor-angiogenesis inhibitors) and radiation therapy.

Cancer Therapeutics Markets - companiesandmarkets.com adds new report  -  Dec 17, 2008
Live-PR.com (Pressemitteilung),Emerging technologies include photodynamic therapy, gene therapy, biological therapy (immunotherapy) and angiogenesis inhibitors.

ERBITUX(R) Supplemental Biologics License Application for Advanced ...  -  Dec 9, 2008
PipelineReview.com (press release),ImClone's research and development programs include growth factor blockers and angiogenesis inhibitors. ImClone's research operations are located in New

Bevacizumab significantly increases venous thromboembolism  -  18 Nov 2008
TheHeart.Org,VTE is an "emerging complication" of many angiogenesis inhibitors, Wu and colleagues write. Thalidomide and its derivative lenalidomide (Revlimid, Celgene),

Bevacizumab Increases VTE Risk  -  18 Nov 2008
MedPage Today,Dr. Wu and colleagues added that increased venous thromboembolism risk might be a class effect of angiogenesis inhibitors. Increased venous thrombosis rates

ARIAD Presents Preclinical Data on Its Kinase Inhibitor, AP24534 ...  -  Oct 24, 2008
MarketWatchCurrently available angiogenesis inhibitors are designed to stop the effects of the protein VEGF on tumors, interfering with the development of new blood

ImClone Systems Announces Clearance of Tender Offer by German ...  -  Nov 17, 2008
WELT ONLINE,ImClone’s research and development programs include growth factor blockers and angiogenesis inhibitors. ImClone Systems’ headquarters and research

Potentia Pharmaceuticals' Drug Candidate for Age-Related Macular ...  -  Nov 10, 2008
MarketWatchThe current standard of care for AMD relies primarily on angiogenesis inhibitors, an approach geared towards the approximately 10-15% of AMD patients with

Phase 2 Study of IMC-1121B in First-Line Treatment of Advanced Non ...  -  Nov 11, 2008
MarketWatchThe Company's research and development programs include growth factor blockers and angiogenesis inhibitors. ImClone Systems' headquarters and research

Taming Vessels to Treat Cancer  -  Nov 10, 2008
Scientific American...originally printed in the January 2008 issue of Scientific American, is being posted in light of two new studies showing that angiogenesis inhibitors,

Timeline: Milestones in Cancer Treatment  -  Oct 25, 2008
Curetoday.com (press release),There is now a class of drugs called angiogenesis inhibitors that shut down a tumor’s blood supply to shrink the tumor. The development of molecular cloning

Is Chronic Inflammation the Key to Unlocking the Mysteries of Cancer?  -  Nov 9, 2008
Scientific American...originally printed in the July 2007 issue of Scientific American, is being posted in light of two new studies showing that angiogenesis inhibitors,

OXiGENE Updates Progress and Reports Third Quarter 2008 Financial ...  -  Nov 4, 2008
Stockhouse,...in various combination regimens with chemotherapy, molecularly-targeted therapies (including tumor-angiogenesis inhibitors), and radiation therapy.

OXiGENE, Inc. Names John A. Kollins As Chief Executive Officer  -  Oct 23, 2008
RedOrbit,...in various combination regimens with chemotherapy, molecularly-targeted therapies (including tumor-angiogenesis inhibitors) and radiation therapy.

ERBITUX(R) Supplemental Biologics License Application for First ...  -  Oct 30, 2008
PR-Inside.com (Pressemitteilung),The Company's research and development programs include growth factor blockers and angiogenesis inhibitors. ImClone Systems' headquarters and research

Study Published in New England Journal of Medicine Shows K-ras ...  -  Oct 23, 2008
PipelineReview.com (press release),The Company's research and development programs include growth factor blockers and angiogenesis inhibitors. ImClone Systems' headquarters and research

Nanotech Revives a Cancer Drug  -  Jul 10, 2008
MIT Technology Review,And compared with traditional chemotherapy and radiation, angiogenesis inhibitors have few side effects. The Children's Hospital drug, called Lodamin in its

New Oral Angiogenesis Inhibitor Offers Potential Nontoxic Therapy ...  -  Jun 30, 2008
Science Daily (press release)While a number of angiogenesis inhibitors, such as Avastin, are now commercially available, most target only single angiogenic factors, such as VEGF,

New oral drug may be effective against a wide range of cancers  -  Jul 1, 2008
News Locale,Dr. Ofra Benny, the developer of Lodamin, describes it as a novel slow-release reformulation of TNP-470, one of the first angiogenesis inhibitors to undergo

Nanomaterials key to new strategies for blocking metastasis  -  Jul 9, 2008
Nanowerk LLC,Although a number of angiogenesis inhibitors, such as Avastin, are now commercially available, most target only single angiogenic factors, such as vascular

Lodamin, a Novel Oral Nanotechnology Formulation, Effective ...  -  Jul 7, 2008
Medi News Direct,As most of the commercially available angiogenesis inhibitors target only a single angiogenic factor, like VEGF, the treatment option is limited to only

Phase 2 Study Of IMC-A12 for Advanced Soft Tissue Sarcoma Opens ...  -  Jul 8, 2008
FOXBusinessThe Company's research and development programs include growth factor blockers and angiogenesis inhibitors. ImClone Systems' headquarters and research

UPI NewsTrack Health and Science News  -  Jul 3, 2008
United Press InternationalIt was one of the first angiogenesis inhibitors to undergo clinical testing. The scientists said Lodamin appears to retain TNP-470's potency and broad

IMC-A12 Plus Temsirolimus Clinical Trial For Advanced Cancer Opens ...  -  Jun 27, 2008
Medical News Today (press release),The Company's research and development programs include growth factor blockers and angiogenesis inhibitors. ImClone Systems' headquarters and research

A Two-Pronged Attack on a Killer  -  Jun 22, 2008
Barron'sDrugs that do this by blocking the formation of new blood vessels -- angiogenesis inhibitors, as they're known in medical circles -- have been playing an

Retinal Vascular Disease  -  Jun 24, 2008
Journal of American Medical Association (subscription),...disappointing to find that the book only briefly mentions the new angiogenesis inhibitors and their use in the treatment of retinal vascular diseases.

Targeted Therapies to Lead New Wave of Breast Cancer Treatments  -  Jun 30, 2008
PR-Inside.com (Pressemitteilung),..."Specialized therapies such as monoclonal antibodies, angiogenesis inhibitors, and vaccines could make a significant impact through targeted mechanisms of

Non-toxic nanotherapy for cancer created  -  Jul 3, 2008
TMCnetIt was one of the first angiogenesis inhibitors to undergo clinical testing. The scientists said Lodamin appears to retain TNP-470's potency and broad

ThromboGenics and BioInvent Announce a Strategic Alliance With ...  -  Jun 17, 2008
PR Newswire (press release),Angiogenesis inhibitors such as TB-403 are therapeutic agents that work by blocking the development of new blood vessels, thereby depriving growing cancer



Background information on Angiogenesis Inhibitors [When available]

One promising avenue of cancer research is the study of a group of compounds called angiogenesis inhibitors. These are drugs that block the development of new blood vessels, a process known as angiogenesis.

By blocking the development of new blood vessels, researchers hope to cut off the tumor's supply of oxygen and nutrients. This in turn might stop the tumor from growing and spreading to other parts of the body.

More from the National Cancer Institute

Search the web for more resources on Angiogenesis Inhibitors



Health Home | Conditions | Cancer | Medications | Surgery | Vaccines


The Cancer News Network


Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on cancernewsnetwork.org lead to other sites. cancernewsnetwork.org does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is CancerNewsNetwork.org responsible for dead or misdirected links.

IF YOU NEED A LINK OR TEXT REMOVED FROM THIS PAGE PLEASE CONTACT cancernewsnetwork (at) live.com.
We will do our best to accommodate your request.



COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy